The DNA cleavage reaction of topoisomerase II: Wolf in sheep's clothing

Nucleic Acids Research

Volumn 37, Issue 3, 2009, Pages 738-748

  Deweese, Joseph E ^a   Osheroff, Neil ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; BENZENE; BIOFLAVONOID; DAUNORUBICIN; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DOUBLE STRANDED DNA; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; ETOPOSIDE; GENISTEIN; IDARUBICIN; MITOXANTRONE; MIXED LINEAGE LEUKEMIA PROTEIN; PARACETAMOL; POLYCHLORINATED BIPHENYL; PROMYELOCYTIC LEUKEMIA PROTEIN; TENIPOSIDE; QUINONE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER; CATALYSIS; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; CYTOTOXICITY; DNA CLEAVAGE; DNA DAMAGE; DNA HELIX; DNA STRUCTURE; DNA SUPERCOILING; DOUBLE STRANDED DNA BREAK; DRUG OVERDOSE; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SOLID TUMOR; CHEMISTRY; DIET; DRUG ANTAGONISM; ENZYMOLOGY; LEUKEMIA; METABOLISM; REVIEW;

OVIS ARIES;

ANTINEOPLASTIC AGENTS; DIET; DNA; DNA CLEAVAGE; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; HUMANS; LEUKEMIA; QUINONES;

EID: 63349086953     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkn937     Document Type: Article

References (156)

1. Loeb,L.A. and Monnat,R.J. Jr. (2008) DNA polymerases and human disease. Nat. Rev. Genet., 9, 594-604.
2. Hedge,M.L., Hazra,T.K. and Mitra,S. (2008) Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res., 18, 27-47.
3. Guengerich,F.P. (2006) Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J., 8, E101-E111.
4. Baguley,B.C. and Ferguson,L.R. (1998) Mutagenic properties of topoisomerase-targeted drugs. Biochim. Biophys. Acta, 1400, 213-222.
5. Fortune,J.M. and Osheroff,N. (2000) Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Prog. Nucleic Acid Res. Mol. Biol., 64, 221-253.
6. Felix,C.A. (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors. Med. Pediatr. Oncol., 36, 525-535.
7. Felix,C.A., Kolaris,C.P. and Osheroff,N. (2006) Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst.), 5 1093-1108.
8. McClendon,A.K. and Osheroff,N. (2007) DNA topoisomerase II, genotoxicity, and cancer. Mutat. Res., 623, 83-97.
9. Nitiss,J.L. (1998) Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta, 1400, 63-81.
10. Wang,J.C. (2002) Cellular roles of DNA topoisomerases: A molecular perspective. Nat. Rev. Mol. Cell Biol., 3, 430-440.
11. Wang,J.C. (1996) DNA topoisomerases. Annu. Rev. Biochem., 65 635-692.
12. Bates,A.D. and Maxwell,A. (2005) DNA Topology. Oxford University Press New York.
13. Kaufmann,S.H. (1998) Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim. Biophys. Acta, 1400, 195-211.
14. Kornberg,A. and Baker,T.A. (1992) DNA Replication. 2nd edn. W. H. Freeman, New York.
15. Voet,D., Voet,J.G. and Pratt,C.W. (2006) Fundamentals of Biochemistry 2nd edn. John Wiley & Sons, Hoboken, N.J.
16. Espeli,O. and Marians,K.J. (2004) Untangling intracellular DNA topology. Mol. Microbiol., 52, 925-931.
17. Falaschi,A., Abdurashidova,G., Sandoval,O., Radulescu,S., Biamonti,G. and Riva,S. (2007) Molecular and structural transactions at human DNA replication origins. Cell Cycle, 6, 1705-1712.
18. Travers,A. and Muskhelishvili,G. (2007) A common topology for bacterial and eukaryotic transcription initiation? EMBO Rep., 8, 147-151.
19. Bauer,W.R., Crick,F.H. and White,J.H. (1980) Supercoiled DNA. Sci. Am., 243, 100-113.
20. Vologodskii,A.V. and Cozzarelli,N.R. (1994) Conformational and thermodynamic properties of supercoiled DNA. Annu. Rev. Biophys. Biomol. Struct., 23, 609-643.
21. White,J.H. and Cozzarelli,N.R. (1984) A simple topological method for describing stereoisomers of DNA catenanes and knots. Proc. Natl Acad. Sci. USA, 81, 3322-3326.
22. Champoux,J.J. (2001) DNA topoisomerases: Structure, function, and mechanism. Annu. Rev. Biochem., 70, 369-413.
23. Schoeffler,A.J. and Berger,J.M. (2005) Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism. Biochem. Soc. Trans., 33, 1465-1470.
24. Leppard,J.B. and Champoux,J.J. (2005) Human DNA topoisomerase I: relaxation, roles, and damage control. Chromosoma, 114, 75-85.
25. Pommier,Y. (2006) Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer, 6, 789-802.
26. Wang,J.C. (1998) Moving one DNA double helix through another by a type II DNA topoisomerase: The story of a simple molecular machine. Quart. Rev. Biophys., 31, 107-144.
27. Berger,J.M., Gamblin,S.J., Harrison,S.C. and Wang,J.C. (1996) Structure and mechanism of DNA topoisomerase II. Nature, 379, 225-232.
28. Velez-Cruz,R. and Osheroff,N. (2004) Encyclopedia of Biological Chemistry. Elsevier Inc., San Diego, CA, pp. 806-811.
29. Osheroff,N. (1986) Eukaryotic topoisomerase II. Characterization of enzyme turnover. J. Biol. Chem., 261, 9944-9950.
30. Osheroff,N. (1987) Role of the divalent cation in topoisomerase II mediated reactions. Biochemistry, 26, 6402-6406.
31. Lindsley,J.E. and Wang,J.C. (1993) On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II. J. Biol. Chem., 268, 8096-8104.
32. Roca,J. and Wang,J.C. (1992) The capture of a DNA double helix by an ATP-dependent protein clamp: A key step in DNA transport by type II DNA topoisomerases. Cell, 71, 833-840.
33. Wilstermann,A.M. and Osheroff,N. (2001) Positioning the 3′-DNA terminus for topoisomerase II-mediated religation. J. Biol. Chem., 276, 17727-17731.
34. Deweese,J.E., Burgin,A.B. and Osheroff,N. (2008) Human topoisomerase IIα uses a two-metal-ion mechanism for DNA cleavage. Nucleic Acids Res., 36, 4883-4893.
35. Goto,T. and Wang,J.C. (1982) Yeast DNA topoisomerase II. An ATP-dependent type II topoisomerase that catalyzes the catenation, decatenation, unknotting, and relaxation of double-stranded DNA rings. J. Biol. Chem., 257, 5866-5872.
36. Goto,T., Laipis,P. and Wang,J.C. (1984) The purification and characterization of DNA topoisomerases I and II of the yeast Saccharomyces cerevisiae. J. Biol. Chem., 259, 10422-10429.
37. Goto,T. and Wang,J.C. (1984) Yeast DNA topoisomerase II is encoded by a single-copy, essential gene. Cell, 36, 1073-1080.
38. Nolan,J.M., Lee,M.P., Wyckoff,E. and Hsieh,T.S. (1986) Isolation and characterization of the gene encoding Drosophila DNA topoisomerase II. Proc. Natl Acad. Sci. USA, 83, 3664-3668.
39. Drake,F.H., Zimmerman,J.P., McCabe,F.L., Bartus,H.F., Per,S.R., Sullivan,D.M., Ross,W.E., Mattern,M.R., Johnson,R.K. and Crooke,S.T. (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J. Biol. Chem. 262, 16739-16747.
40. Tsai-Pflugfelder,M., Liu,L.F., Liu,A.A., Tewey,K.M., Whang-Peng,J., Knutsen,T., Huebner,K., Croce,C.M. and Wang,J.C. (1988) Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc. Natl Acad. Sci. USA 85, 7177-7181.
41. Drake,F.H., Hofmann,G.A., Bartus,H.F., Mattern,M.R., Crooke,S.T. and Mirabelli,C.K. (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry, 28, 8154-8160.
42. Chung,T.D., Drake,F.H., Tan,K.B., Per,S.R., Crooke,S.T. and Mirabelli,C.K. (1989) Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc. Natl Acad. Sci. USA, 86, 9431-9435.
43. Austin,C.A. and Fisher,L.M. (1990) Isolation and characterization of a human cDNA clone encoding a novel DNA topoisomerase II homologue from HeLa cells. FEBS Lett., 266, 115-117.
44. Jenkins,J.R., Ayton,P., Jones,T., Davies,S.L., Simmons,D.L., Harris,A.L., Sheer,D. and Hickson,I.D. (1992) Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res., 20, 5587-5592.
45. Tan,K.B., Dorman,T.E., Falls,K.M., Chung,T.D., Mirabelli,C.K., Crooke,S.T. and Mao,J. (1992) Topoisomerase II alpha and topoisomerase II beta genes: Characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res., 52, 231-234.
46. Wilstermann,A.M. and Osheroff,N. (2003) Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr. Top. Med. Chem., 3, 321-338.
47. McClendon,A.K., Rodriguez,A.C. and Osheroff,N. (2005) Human topoisomerase IIα rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks. J. Biol. Chem., 280, 39337-39345.
48. Heck,M.M. and Earnshaw,W.C. (1986) Topoisomerase II: A specific marker for cell proliferation. J. Cell Biol., 103, 2569-2581.
49. Hsiang,Y.H., Wu,H.Y. and Liu,L.F. (1988) Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res., 48, 3230-3235.
50. Woessner,R.D., Mattern,M.R., Mirabelli,C.K., Johnson,R.K. and Drake,F.H. (1991) Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ., 2, 209-214.
51. Grue,P., Grasser,A., Sehested,M., Jensen,P.B., Uhse,A., Straub,T., Ness,W. and Boege,F. (1998) Essential mitotic functions of DNA topoisomerase IIα are not adopted by topoisomerase IIβ in human H69 cells. J. Biol. Chem., 273, 33660-33666.
52. Heck,M.M., Hittelman,W.N. and Earnshaw,W.C. (1988) Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc. Natl Acad. Sci. USA, 85, 1086-1090.
53. Kimura,K., Saijo,M., Ui,M. and Enomoto,T. (1994) Growth state-and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase. J. Biol. Chem., 269, 1173-1176.
54. Linka,R.M., Porter,A.C., Volkov,A., Mielke,C., Boege,F. and Christensen,M.O. (2007) C-terminal regions of topoisomerase IIα and IIβ determine isoform-specific functioning of the enzymes in vivo. Nucleic Acids Res., 35, 3810-3822.
55. Bauman,M.E., Holden,J.A., Brown,K.A., Harker,W.G. and Perkins,S.L. (1997) Differential immunohistochemical staining for DNA topoisomerase IIα and β in human tissues and for DNA topoisomerase IIβ in non-Hodgkin's lymphomas. Mod. Pathol., 10, 168-175.
56. Christensen,M.O., Larsen,M.K., Barthelmes,H.U., Hock,R., Andersen,C.L., Kjeldsen,E., Knudsen,B.R., Westergaard,O., Boege,F. and Mielke,C. (2002) Dynamics of human DNA topoisomerases IIα and IIβ in living cells. J. Cell Biol., 157, 31-44.
57. Chen,M. and Beck,W.T. (1995) DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Oncol. Res., 7, 103-111.
58. Dereuddre,S., Delaporte,C. and Jacquemin-Sablon,A. (1997) Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors. Cancer Res., 57, 4301-4308.
59. Yang,X., Li,W., Prescott,E.D., Burden,S.J. and Wang,J.C. (2000) DNA topoisomerase IIβ and neural development. Science, 287, 131-134.
60. Austin,C.A. and Marsh,K.L. (1998) Eukaryotic DNA topoisomerase IIβ. BioEssays, 20, 215-226.
61. Isaacs,R.J., Davies,S.L., Sandri,M.I., Redwood,C., Wells,N.J. and Hickson,I.D. (1998) Physiological regulation of eukaryotic topoisomerase II. Biochim. Biophys. Acta, 1400, 121-137.
62. Sakaguchi,A. and Kikuchi,A. (2004) Functional compatibility between isoform alpha and beta of type II DNA topoisomerase. J. Cell Sci., 117, 1047-1054.
63. Ju,B.G., Lunyak,V.V., Perissi,V., Garcia-Bassets,I., Rose,D.W., Glass,C.K. and Rosenfeld,M.G. (2006) A topoisomerase IIβ-mediated dsDNA break required for regulated transcription. Science, 312, 1798-1802.
64. Haince,J.F., Rouleau,M. and Poirier,G.G. (2006) Transcription. Gene expression needs a break to unwind before carrying on. Science, 312, 1752-1753.
65. Zechiedrich,E.L., Christiansen,K., Andersen,A.H., Westergaard,O. and Osheroff,N. (1989) Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: Evidence for a nicked DNA intermediate. Biochemistry, 28, 6229-6236.
66. Liu,L.F., Rowe,T.C., Yang,L., Tewey,K.M. and Chen,G.L. (1983) Cleavage of DNA by mammalian DNA topoisomerase II. J. Biol. Chem., 258 15365-15370.
67. Sander,M. and Hsieh,T. (1983) Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster. J. Biol. Chem., 258 8421-8428.
68. Capranico,G. and Binaschi,M. (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim. Biophys. Acta, 1400, 185-194.
69. Velez-Cruz,R., Riggins,J.N., Daniels,J.S., Cai,H., Guengerich,F.P., Marnett,L.J. and Osheroff,N. (2005) Exocyclic DNA lesions stimulate DNA cleavage mediated by human topoisomerase IIα in vitro and in cultured cells. Biochemistry, 44, 3972-3981.
70. Dong,K.C. and Berger,J.M. (2007) Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature, 450 1201-1205.
71. Aravind,L., Leipe,D.D. and Koonin,E.V. (1998) Toprim-a conserved catalytic domain in type IA and II topoisomerases, DnaG-type primases, OLD family nucleases and RecR proteins. Nucleic Acids Res., 26 4205-4213.
72. Berger,J.M., Fass,D., Wang,J.C. and Harrison,S.C. (1998) Structural similarities between topoisomerases that cleave one or both DNA strands. Proc. Natl Acad. Sci. USA, 95, 7876-7881.
73. Noble,C.G. and Maxwell,A. (2002) The role of GyrB in the DNA cleavage-religation reaction of DNA gyrase: A proposed two metal-ion mechanism. J. Mol. Biol., 318, 361-371.
74. West,K.L., Meczes,E.L., Thorn,R., Turnbull,R.M., Marshall,R. and Austin,C.A. (2000) Mutagenesis of E477 or K505 in the B' domain of human topoisomerase II beta increases the requirement for magnesium ions during strand passage. Biochemistry, 39, 1223-1233.
75. Leontiou,C., Lakey,J.H., Lightowlers,R., Turnbull,R.M. and Austin,C.A. (2006) Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance. Mol. Pharmacol., 69, 130-139.
76. Bender,R.P. and Osheroff,N. (2008) DNA topoisomerases as targets for the chemotherapeutic treatment of cancer. In Dai,W. (ed.), Checkpoint Responses in Cancer Therapy. Humana Press, Totowa, NJ, pp. 57-91.
77. Mueller-Planitz,F. and Herschlag,D. (2008) Coupling between ATP binding and DNA cleavage by DNA topoisomerase II: A unifying kinetic and structural mechanism. J. Biol. Chem., 283, 17463-17476.
78. Deweese,J.E., Burgin,A.B. and Osheroff,N. (2008) Using 3′-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIα. Biochemistry, 47, 4129-4140.
79. Andersen,A.H., Christiansen,K., Zechiedrich,E.L., Jensen,P.S., Osheroff,N. and Westergaard,O. (1989) Strand specificity of the topoisomerase II mediated double-stranded DNA cleavage reaction. Biochemistry, 28, 6237-6244.
80. Bromberg,K.D., Burgin,A.B. and Osheroff,N. (2003) A two-drug model for etoposide action against human topoisomerase IIα. J. Biol. Chem., 278, 7406-7412.
81. D'Arpa,P., Beardmore,C. and Liu,L.F. (1990) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res., 50, 6919-6924.
82. Pommier,Y. and Marchand,C. (2005) Interfacial inhibitors of protein-nucleic acid interactions. Curr. Med. Chem. Anticancer Agents 5, 421-429.
83. Burden,D.A., Kingma,P.S., Froelich-Ammon,S.J., Bjornsti,M.-A., Patchan,M.W., Thompson,R.B. and Osheroff,N. (1996) Topoisomerase II-etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J. Biol. Chem., 271, 29238-29244.
84. Kingma,P.S., Burden,D.A. and Osheroff,N. (1999) Binding of etoposide to topoisomerase II in the absence of DNA: Decreased affinity as a mechanism of drug resistance. Biochemistry, 38, 3457-3461.
85. Leroy,D., Kajava,A.V., Frei,C. and Gasser,S.M. (2001) Analysis of etoposide binding to subdomains of human DNA topoisomerase IIα in the absence of DNA. Biochemistry, 40, 1624-1634.
86. Li,T.K. and Liu,L.F. (2001) Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol., 41, 53-77.
87. Walker,J.V. and Nitiss,J.L. (2002) DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest., 20, 570-589.
88. Capranico,G., Guano,F., Moro,S., Zagotto,G., Sissi,C., Gatto,B., Zunino,F., Menta,E. and Palumbo,M. (1998) Mapping drug interactions at the covalent topoisomerase II-DNA complex by bisantrene/amsacrine congeners. J. Biol. Chem., 273, 12732-12739.
89. Lindsey,R.H. Jr, Bromberg,K.D., Felix,C.A. and Osheroff,N. (2004) 1,4-Benzoquinone is a topoisomerase II poison. Biochemistry, 43 7563-7574.
90. Bandele,O.J. and Osheroff,N. (2008) (-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases. Chem. Res. Toxicol., 21, 936-943.
91. Wang,H., Mao,Y., Chen,A.Y., Zhou,N., LaVoie,E.J. and Liu,L.F. (2001) Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. Biochemistry, 40, 3316-3323.
92. Bender,R.P. and Osheroff,N. (2007) Mutation of cysteine residue 455 to alanine in human topoisomerase IIα confers hypersensitivity to quinones: Enhancing DNA scission by closing the N-terminal protein gate. Chem. Res. Toxicol., 20, 975-981.
93. Bender,R.P., Ham,A.J. and Osheroff,N. (2007) Quinone-induced enhancement of DNA cleavage by human topoisomerase IIα: Adduction of cysteine residues 392 and 405. Biochemistry, 46, 2856-2864.
94. Bender,R.P., Lehmler,H.J., Robertson,L.W., Ludewig,G. and Osheroff,N. (2006) Polychlorinated biphenyl quinone metabolites poison human topoisomerase IIα: Altering enzyme function by blocking the N-terminal protein gate. Biochemistry, 45, 10140-10152.
95. Lindsey,R.H. Jr, Bender,R.P. and Osheroff,N. (2005) Effects of benzene metabolites on DNA cleavage mediated by human topoisomerase IIα: 1,4-hydroquinone is a topoisomerase II poison. Chem. Res. Toxicol. 18, 761-770.
96. Bender,R.P., Lindsey,R.H. Jr, Burden,D.A. and Osheroff,N. (2004) N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison. Biochemistry, 43, 3731-3739.
97. Frydman,B., Marton,L.J., Sun,J.S., Neder,K., Witiak,D.T., Liu,A.A., Wang,H.M., Mao,Y., Wu,H.Y., Sanders,M.M. et al. (1997) Induction of DNA topoisomerase II-mediated DNA cleavage by beta-lapachone and related naphthoquinones. Cancer Res., 57, 620-627.
98. Frantz,C.E., Chen,H. and Eastmond,D.A. (1996) Inhibition of human topoisomerase II in vitro by bioactive benzene metabolites. Environ. Health Perspect., 104(Suppl. 6), 1319-1323.
99. Baker,R.K., Kurz,E.U., Pyatt,D.W., Irons,R.D. and Kroll,D.J. (2001) Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIα. Blood, 98, 830-833.
100. Baldwin,E.L. and Osheroff,N. (2005) Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anticancer Agents, 5, 363-372.
101. Martincic,D. and Hande,K.R. (2005) Topoisomerase II inhibitors. Cancer Chemother. Biol. Response Modif., 22, 101-121.
102. Hande,K.R. (1998) Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer, 34, 1514-1521.
103. Kell,J. (2006) Treatment of relapsed acute myeloid leukaemia. Rev. Recent Clin. Trials, 1, 103-111.
104. Coley,H.M. (2008) Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat. Rev., 34 378-390.
105. Burden,D.A. and Osheroff,N. (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1400, 139-154.
106. Gold,R. (2008) Combination therapies in multiple sclerosis. J. Neurol., 255(Suppl. 1), 51-60.
107. Azarova,A.M., Lyu,Y.L., Lin,C.P., Tsai,Y.C., Lau,J.Y., Wang,J.C. and Liu,L.F. (2007) Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl Acad. Sci. USA, 104, 11014-11019.
108. Lyu,Y.L., Lin,C.P., Azarova,A.M., Cai,L., Wang,J.C. and Liu,L.F. (2006) Role of topoisomerase IIβ in the expression of developmentally regulated genes. Mol. Cell Biol., 26, 7929-7941.
109. Sehested,M., Jensen,P.B., Sorensen,B.S., Holm,B., Friche,E. and Demant,E.J. (1993) Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem. Pharmacol., 46, 389-393.
110. Constantinou,A., Mehta,R., Runyan,C., Rao,K., Vaughan,A. and Moon,R. (1995) Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J. Nat. Prod., 58, 217-225.
111. Strick,R., Strissel,P.L., Borgers,S., Smith,S.L. and Rowley,J.D. (2000) Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc. Natl Acad. Sci. USA, 97, 4790-4795.
112. Martin-Cordero,C., Lopez-Lazaro,M., Pinero,J., Ortiz,T., Cortes,F. and Ayuso,M.J. (2000) Glucosylated isoflavones as DNA topoisomerase II poisons. J. Enzyme Inhib., 15, 455-460.
113. Galati,G. and O'Brien,P.J. (2004) Potential toxicity of flavonoids and other dietary phenolics: Significance for their chemopreventive and anticancer properties. Free Radic. Biol. Med., 37, 287-303.
114. Adlercreutz,H., Markkanen,H. and Watanabe,S. (1993) Plasma concentrations of phyto-oestrogens in Japanese men. Lancet, 342 1209-1210.
115. Lamartiniere,C.A. (2000) Protection against breast cancer with genistein: A component of soy. Am. J. Clin. Nutr., 71, 1705S-1707S; discussion 1708S-1709S.
116. Siddiqui,I.A., Adhami,V.M., Saleem,M. and Mukhtar,H. (2006) Beneficial effects of tea and its polyphenols against prostate cancer. Mol. Nutr. Food Res., 50, 130-143.
117. Sarkar,F.H., Adsule,S., Padhye,S., Kulkarni,S. and Li,Y. (2006) The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev. Med. Chem., 6, 401-407.
118. Markovits,J., Linassier,C., Fosse,P., Couprie,J., Pierre,J., Jacquemin-Sablon,A., Saucier,J.M., Le Pecq,J.B. and Larsen,A.K. (1989) Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res., 49, 5111-5117.
119. Austin,C.A., Patel,S., Ono,K., Nakane,H. and Fisher,L.M. (1992) Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem. J., 282, 883-889.
120. Markovits,J., Junqua,S., Goldwasser,F., Venuat,A.M., Luccioni,C., Beaumatin,J., Saucier,J.M., Bernheim,A. and Jacquemin-Sablon,A. (1995) Genistein resistance in human leukaemic CCRF-CEM cells: Selection of a diploid cell line with reduced DNA topoisomerase II beta isoform. Biochem. Pharmacol., 50, 177-186.
121. Bandele,O.J., Clawson,S.J. and Osheroff,N. (2008) Dietary polyphenols as topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage enhancement. Chem. Res. Toxicol., 21, 1253-1260.
122. Bandele,O.J. and Osheroff,N. (2007) Bioflavonoids as poisons of human topoisomerase IIα and IIβ. Biochemistry, 46, 6097-6108.
123. Ross,J.A., Potter,J.D. and Robison,L.L. (1994) Infant leukemia, topoisomerase II inhibitors, and the MLL gene. J. Natl. Cancer Inst. 86, 1678-1680.
124. Ross,J.A., Potter,J.D., Reaman,G.H., Pendergrass,T.W. and Robison,L.L. (1996) Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): A report from the Children's Cancer Group. Cancer Causes Control, 7, 581-590.
125. Ross,J.A. (2000) Dietary flavonoids and the MLL gene: A pathway to infant leukemia? Proc. Natl Acad. Sci. USA, 97, 4411-4413.
126. Spector,L.G., Xie,Y., Robison,L.L., Heerema,N.A., Hilden,J.M., Lange,B., Felix,C.A., Davies,S.M., Slavin,J., Potter,J.D. et al. (2005) Maternal diet and infant leukemia: The DNA topoisomerase II inhibitor hypothesis: A report from the children's oncology group. Cancer Epidemiol. Biomarkers Prev., 14, 651-655.
127. Anderson,V.E. and Osheroff,N. (2001) Type II topoisomerases as targets for quinolone antibacterials: Turning Dr. Jekyll into Mr. Hyde. Curr. Pharm. Des., 7, 337-353.
128. Drlica,K. and Malik,M. (2003) Fluoroquinolones: Action and resistance. Curr. Top. Med. Chem., 3, 249-282.
129. Levine,C., Hiasa,H. and Marians,K.J. (1998) DNA gyrase and topoisomerase IV: Biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. Biophys. Acta, 1400, 29-43.
130. Ross,D. (2000) The role of metabolism and specific metabolites in benzene-induced toxicity: Evidence and issues. J. Toxicol. Environ. Health A., 61, 357-372.
131. Lindsey,R.H., Bender,R.P. and Osheroff,N. (2005) Stimulation of topoisomerase II-mediated DNA cleavage by benzene metabolites. Chem. Biol. Interact., 153-154, 197-205.
132. Shen,Y., Shen,H.M., Shi,C.Y. and Ong,C.N. (1996) Benzene metabolites enhance reactive oxygen species generation in HL60 human leukemia cells. Hum. Exp. Toxicol., 15, 422-427.
133. Kuo,M.L., Shiah,S.G., Wang,C.J. and Chuang,S.E. (1999) Suppression of apoptosis by Bcl-2 to enhance benzene metabolites-induced oxidative DNA damage and mutagenesis: A possible mechanism of carcinogenesis. Mol. Pharmacol., 55, 894-901.
134. Lovern,M.R., Cole,C.E. and Schlosser,P.M. (2001) A review of quantitative studies of benzene metabolism. Crit. Rev. Toxicol., 31, 285-311.
135. Rappaport,S.M., Waidyanatha,S., Qu,Q., Shore,R., Jin,X., Cohen,B., Chen,L.C., Melikian,A.A., Li,G., Yin,S. et al. (2002) Albumin adducts of benzene oxide and 1,4-benzoquinone as measures of human benzene metabolism. Cancer Res., 62, 1330-1337.
136. Prescott,L.F. (2000) Paracetamol: Past, present, and future. Am. J. Ther., 7, 143-147.
137. Kingma,P.S., Greider,C.A. and Osheroff,N. (1997) Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. Biochemistry, 36, 5934-5939.
138. Kingma,P.S. and Osheroff,N. (1997) Apurinic sites are position-specific topoisomerase II-poisons. J. Biol. Chem., 272, 1148-1155.
139. Kingma,P.S. and Osheroff,N. (1997) Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage. J. Biol. Chem., 272, 7488-7493.
140. Kingma,P.S. and Osheroff,N. (1998) The response of eukaryotic topoisomerases to DNA damage. Biochim. Biophys. Acta, 1400, 223-232.
141. Cline,S.D., Jones,W.R., Stone,M.P. and Osheroff,N. (1999) DNA abasic lesions in a different light: Solution structure of an endogenous topoisomerase II poison. Biochemistry, 38, 15500-15507.
142. Cline,S.D. and Osheroff,N. (1999) Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by human type II enzymes. J. Biol. Chem., 274, 29740-29743.
143. Sabourin,M. and Osheroff,N. (2000) Sensitivity of human type II topoisomerases to DNA damage: Stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic Acids Res., 28, 1947-1954.
144. Khan,Q.A., Kohlhagen,G., Marshall,R., Austin,C.A., Kalena,G.P., Kroth,H., Sayer,J.M., Jerina,D.M. and Pommier,Y. (2003) Position-specific trapping of topoisomerase II by benzo[a]-pyrene diol epoxide adducts: Implications for interactions with intercalating anticancer agents. Proc. Natl Acad. Sci. USA, 100, 12498-12503.
145. Solovyan,V.T., Bezvenyuk,Z.A., Salminen,A., Austin,C.A. and Courtney,M.J. (2002) The role of topoisomerase II in the excision of DNA loop domains during apoptosis. J. Biol. Chem., 277, 21458-21467.
146. Belyaev,I.Y. (2005) DNA loop organization and DNA fragmentation during radiation-induced apoptosis in human lymphocytes. Radiats. Biol. Radioecol., 45, 541-548.
147. Felix,C.A., Hosler,M.R., Winick,N.J., Masterson,M., Wilson,A.E. and Lange,B.J. (1995) ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood, 85, 3250-3256.
148. Felix,C.A. (1998) Secondary leukemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta, 1400, 233-255.
149. Hasan,S.K., Mays,A.N., Ottone,T., Ledda,A., La Nasa,G., Cattaneo,C., Borlenghi,E., Melillo,L., Montefusco,E., Cervera,J. et al. (2008) Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood, 112, 3383-3390
150. Mistry,A.R., Felix,C.A., Whitmarsh,R.J., Mason,A., Reiter,A., Cassinat,B., Parry,A., Walz,C., Wiemels,J.L., Segal,M.R. et al. (2005) DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N. Engl. J. Med., 352, 1529-1538.
151. Gilliland,D.G., Jordan,C.T. and Felix,C.A. (2004) The molecular basis of leukemia. Hematol. Am. Soc. Hematol. Educ. Program, 80-97.
152. Errington,F., Willmore,E., Tilby,M.J., Li,L., Li,G., Li,W., Baguley,B.C. and Austin,C.A. (1999) Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: Analysis of cytotoxicity and cleavable complex formation. Mol. Pharmacol., 56, 1309-1316.
153. Willmore,E., Frank,A.J., Padget,K., Tilby,M.J. and Austin,C.A. (1998) Etoposide targets topoisomerase IIα and IIβ in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol. Pharm., 54, 78-85.
154. Bandele,O.J. and Osheroff,N. (2008) The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells. Biochemistry, 47, 11900-11908.
155. Beese,L.S., Friedman,J.M. and Steitz,T.A. (1993) Crystal structures of the Klenow fragment of DNA polymerase I complexed with deoxynucleoside triphosphate and pyrophosphate. Biochemistry, 32, 14095-14101.
156. Curley,J.F., Joyce,C.M. and Piccirilli,J.A. (1997) Functional evidence that the 3′-5′ exonuclease domain of Escherichia coli DNA polymerase I employs a divalent metal ion in leaving group stabilization. J. Am. Chem. Soc, 119, 12691-12692.